AbCellera Biologics WKN: A2QKXS ISIN: CA00288U1066 Kürzel: ABCL Forum: Aktien Thema: Hauptdiskussion

Truist Securities Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $29. Truist Securities analyst Robyn Karnauskas initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Buy rating and announces Price Target of $29. https://www.webullapp.com/news-detail/7660739051940864?__app_cfg__=%7B%22supportTheme%22%3Atrue%7D&sourcePage=StockNews&tickerId=950178304&disSymbol=ABCL&theme=1&color=2&hl=en&android_sdk_int=29&canary-version=&_v=1&sp=1&statusBarHeightV2=36&wbFontSetting=medium&wbFontUnit=30&wbFontSize=30&isSubsNews=false

💯

https://investors.abcellera.com/news/news-releases/2022/AbCellera-Presents-New-Data-on-Further-Development-and-Characterization-of-T-Cell-Engager-Platform-at-SITC-2022/default.aspx

https://investors.abcellera.com/news/news-releases/2022/AbCellera-Reports-Q3-2022-Business-Results/default.aspx

https://investors.abcellera.com/news/news-releases/2022/AbCellera-to-Present-at-Upcoming-Investor-Conferences-in-November/default.aspx

https://investors.abcellera.com/news/news-releases/2022/AbCelleras-First-Program-with-Regeneron-in-Multi-Target-Collaboration-Advances-in-Preclinical-Development/default.aspx

👍🏻👌

https://www.globenewswire.com/news-release/2022/09/30/2525812/28124/en/Global-Monoclonal-Antibodies-mAbs-Market-Analysis-Report-2022-A-Projected-494-53-Billion-Market-by-2030.html

Phase II https://www.novarockbio.com/novarock-biotherapeutics-announces-exclusive-license-agreement-with-cspc-to-develop-and-commercialize-nbl-012-in-select-international-territories/

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00592-8/fulltext

https://www.investors.com/research/abcellera-biologics-inc-earns-rs-rating-upgrade/

https://investors.abcellera.com/news/news-releases/2022/AbCellera-to-Report-Third-Quarter-2022-Financial-Results-on-November-8-2022/default.aspx

https://investors.abcellera.com/news/news-releases/2022/AbCellera-Announces-Presentation-of-Data-from-CD3-T-Cell-Engager-Platform-at-SITC-2022/default.aspx

https://investors.abcellera.com/news/news-releases/2022/AbCellera-Launches-Second-Phase-of-Global-Headquarters-Expansion-to-Advance-Capabilities-for-Bringing-New-Medicines-from-Target-to-the-Clinic/default.aspx

https://www.linkedin.com/posts/abcellera_breaking-ground-on-phase-ii-of-our-380k-sq-activity-6975867267515392001-JZEL?utm_source=share&utm_medium=member_ios

AbCellera Biologics ist eine unterbewertete, profitable Wirkstoffforschungsaktie mit einer Marktkapitalisierung von 3 Mrd. USD. AbCellera Biologics hat eine makellose Bilanz ohne Schulden in den letzten fünf Jahren und 1,1 Mrd. $ an liquiden Mitteln. Dieses Unternehmen verfügt über eine Kapital- und Betriebseffizienz, die zu aktuellen Bruttomargen von fast 74 % und Nettogewinnmargen von 39,5 % führt. Partnerschaften mit pharmazeutischen Unternehmen und Risikokapitalfirmen für Arzneimittelentdeckungen wachsen weiter.